Skip to main content

Table 3 Characteristics of exchange transfusion patients according to outcome

From: Risk factors and mortality in children with severe pertussis: the role of exchange transfusion in a PICU

Variables

Total (n = 39)

Survivors (n = 23)

Deceased (n = 16)

P

Age (day), M (IQR)

71 (51, 192)

94(54, 244)

63 (40, 94)

0.050

Gender (male), n(%)

22 (56.41)

11 (47.83)

11 (68.75)

0.325

Immunization, n(%)

17 (43.59)

12 (52.17)

5 (31.25)

0.325

WBC (× 109/l),M (IQR)

66.12 (55.26, 83.10)

62.40 (50.43, 70.32)

80.06 (59.24, 92.89)

0.017

Lymphocytic absolute value, M (IQR)

28.22 (23.40, 37.78)

28.22 (22.88, 39.40)

27.41 (24.56, 34.91)

0.944

Neutrophils absolute value, M (IQR)

27.57 (20.33, 39.46)

22.47 (18.27, 31.67)

42.75 (28.19, 53.60)

 <.001

Monocytes absolute value, M (IQR)

2.84 (2.12, 4.57)

2.45 (2.03, 3.98)

3.76 (2.27, 4.91)

0.199

PLT (× 109/l), M (IQR)

620 (527, 743)

620 (547, 743)

655(508, 742)

0.989

CRP (mg/l), M (IQR)

18 (8, 34)

8 (8, 22)

32 (16, 44)

0.019

PCT (ng/ml), M (IQR)

0.13 (0.08, 0.33)

0.10 (0.07, 0.26)

0.16 (0.12, 0.34)

0.106

Bilirubin (μmol/l), M (IQR)

6.30 (3.00, 13.15)

6.00 (1.95, 9.60)

9.45 (4.60, 18.77)

0.153

ALT (U/L), M (IQR)

30.60 (19.50, 42.70)

32.20 (21.00, 48.80)

24.50 (18.75, 33.50)

0.145

Creatinine (μmol/l), M (IQR)

21.00 (16.00, 25.20)

21.00 (16.00, 23.45)

19.55 (14.00, 26.50)

0.864

PCO2(mmHg), M (IQR)

49.00 (40.40, 55.05)

43.40 (39.60, 53.50)

51.85 (42.70, 59.62)

0.242

PO2(mmHg), M (IQR)

78.20 (61.50, 97.20)

65.10 (58.00, 88.95)

87.05 (73.07, 163.25)

0.009

PH, n(%)

3 (7.69)

2 (8.70)

1 (6.25)

1.000

Epilepsy, n(%)

3 (7.69)

2 (8.70)

1 (6.25)

1.000

Hypoproteinemia, n(%)

16 (41.03)

8 (34.78)

8 (50.00)

0.509

Sepsis, n(%)

6 (15.38)

1 (4.35)

5 (31.25)

0.033

Shock, n(%)

19 (48.72)

4 (17.39)

15 (93.75)

 <.001

Respiratory failure, n(%)

37 (94.87)

23 (100.00)

14 (87.50)

0.162

ARDS, n(%)

3 (7.69)

0 (0.00)

3 (18.75)

0.061

Myocardial injury, n(%)

16 (41.03)

8 (34.78)

8 (50.00)

0.509

Hepatic injury, n(%)

5 (12.82)

3 (13.04)

2 (12.50)

1.000

AKI, n(%)

3 (7.69)

0 (0.00)

3 (18.75)

0.061

Other respiratory pathogen infectionsa, n(%)

29 (74.36)

16 (69.57)

13 (81.25)

0.480

Atelectasis, n(%)

12 (30.77)

10 (43.48)

2 (12.50)

0.076

Lung consolidation, n(%)

31 (79.49)

19 (82.61)

12 (75.00)

0.694

Vasoactive drugs, n(%)

29 (74.36)

13 (56.52)

16 (100.00)

0.002

Albumin, n(%)

38 (97.44)

22 (95.65)

16 (100.00)

1.000

Hormones, n(%)

20 (51.28)

12 (52.17)

8 (50.00)

1.000

IVIG, n(%)

24 (61.54)

16 (69.57)

8 (50.00)

0.318

Ventilator, n(%)

38 (97.44)

22 (95.65)

16 (100.00)

1.000

High frequency ventilation, n(%)

5 (12.82)

2 (8.70)

3 (18.75)

0.631

Invasive ventilation, n(%)

36 (92.31)

21 (91.30)

15 (93.75)

1.000

  1. ALT Alanine transaminase, AKI Acute kidney injury, ARDS Acute respiratory distress syndrome, CRP C-reactive protein, IQR Interquartile range, IVIG Intravenous immune globulin, M Median, PCT Procalcitonin, PCO2 Partial pressure of carbon dioxide, PO2 Oxygen partial pressure, PLT Platelet, PH Pulmonary arterial hypertension, WBC White blood cells
  2. aOther respiratory pathogen infections include the following pathogens: Adenovirus, Epstein-Barr Virus, Bocavirus, Parainfluenza Virus, Coronavirus, Respiratory Syncytial Virus, Influenza Virus, Acinetobacter baumannii, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella catarrhalis, Enterobacter aerogenes, Serratia marcescens, Leminospira nodosa, Methicillin-Resistant Staphylococcus aureus, Elizabethkingia meningoseptica, Klebsiella oxytoca, Achromobacter xylosoxidans, Pseudomonas aeruginosa, Lysinibacillus sphaericus, Candida albicans, Chlamydia pneumoniae, Mycoplasma pneumoniae, Chlamydia, Chlamydia trachomatis, and others
Back to article page

Italian Journal of Pediatrics

ISSN: 1824-7288

Contact us